24 Oct 2017,
  • HSI:
    28,305.88 -181.36 (-0.64%)
    HSCI:
    11,491.07 -67.28 (-0.58%)
    HKSPLC25:
    36,328.23 -221.48 (-0.61%)
    HKSPGEM:
    277.06 -0.55 (-0.20%)
  • HSCEI:
    11,491.07 -67.28 (-0.58%)
    HSCCI:
    4,394.17 -1.23 (-0.03%)
    HSFML25:
    9,962.34 -50.63 (-0.51%)
    H-FIN:
    18,492.56 -47.12 (-0.25%)
  • Hang Seng Index
  • 28,305.88

  • -181.36 (-0.64%)
HSCI 11,491.1 -67.3
HKSPLC25 36,328.2 -221.5
HKSPGEM 277.1 -0.6
HSCEI 11,491.1 -67.3
HSCCI 4,394.2 -1.2
HSFML25 9,962.3 -50.6
H-FIN 18,492.6 -47.1
Stay Connected With EQS TodayIR

Sinopharm Group Co. Ltd. (01099.HK)

Pharmaceuticals

INTRADAY CHART

more

FINANCIAL REPORTSmore

2017 (IR)
2016 (AR)
2016 (IR)

PRESENTATIONSmore

  • 2017 Interim ...
    2017
  • 2016 Annual R ...
    2017
  • 2016 Interim ...
    2016
Sinopharm Group Co. Ltd. (the “Company” or “Sinopharm Group”, together with its subsidiaries referred to as the “Group”), which was established in January 2003 and listed on The Stock Exchange of Hong Kong Limited (the “Hong Kong Stock Exchange”) (stock code: 01099. HK) in September 2009, is a core subsidiary of China National Pharmaceutical Group Corporation (“CNPGC”) and the largest wholesaler and retailer of pharmaceutical and healthcare products and a leading supply-chain service provider in the PRC.

The Group is mainly engaged in pharmaceutical distribution business. Leveraging on its nationwide distribution and delivery network, the Group provides comprehensive distribution, logistics and other value-added services to domestic and foreign manufacturer and suppliers of pharmaceutical products, medical equipment and supplies and other healthcare products, and also to downstream customers including hospitals, other distributors, retail drug stores and primary health services institutions.

Meanwhile, the Group manages its network of retail drug stores chain in major cities of China via direct operations and franchises to sell pharmaceutical and healthcare products to end-customers. It has become a leader in China’s pharmaceutical retail industry.

Besides, the Group is also engaged in the production and sale of pharmaceutical products, chemical reagents and laboratory supplies, and actively engaged in the innovation of pharmaceutical, medical services, finance leasing and other health-related industries, to explore the synergistic development of its diversified businesses.

Taking advantage of its superior economies of scale, customer resources, network platforms and brand position, the Group will fully leverage on China’s pharmaceutical and healthcare market, which shows steady and healthy growth, and capture opportunities arising from healthcare reform to further consolidate and enhance its market leadership, actively striving to become a pharmaceutical and healthcare service provider with international competitiveness.
+ More Company Profile
Procedures for Shareholders to Propose a Person for Election as a Director
 

UPCOMING EVENT

S M T W T F S
1 2 3 4 5 6 7
8 9 10 11 12 13 14
15 16 17 18 19 20 21
22 23 24 25 26 27 28
29 30 31        

COMPANY INFORMATION

Listed Date 23 Sep 2009

Address 27/F 01, Floor 27,
148 Electric Road,
North Point, Hong Kong

Telephone (86 21) 6321 1750

Email sinopharm@wsfg.hk

No. of Click Rate

161411